Terms: = Prostate cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Prognosis
13 results:
1. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract] [Full Text] [Related]
2. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
3. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
4. Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts.
Li Z; Jia Y; Zhu H; Yuan H; Xing X; Xin Y; Ma T; Pang F; Zhang Y; Hu Y; Jia S; Ji J
Int J Cancer; 2022 Oct; 151(8):1382-1393. PubMed ID: 35567574
[TBL] [Abstract] [Full Text] [Related]
5. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract] [Full Text] [Related]
6. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC; Halabi S; Somarelli JA; Humeniuk M; Wu Y; Oyekunle T; Howard L; Huang J; Anand M; Davies C; Patel P; Staats J; Weinhold KJ; Harrison MR; Zhang T; George DJ; Armstrong AJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):762-769. PubMed ID: 35292724
[TBL] [Abstract] [Full Text] [Related]
7. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
Wu J; Wei Y; Pan J; Jin S; Gu W; Gan H; Zhu Y; Ye DW
Int J Cancer; 2021 Feb; 148(3):673-681. PubMed ID: 33006389
[TBL] [Abstract] [Full Text] [Related]
8. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 prostate cancer.
Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
[TBL] [Abstract] [Full Text] [Related]
9. cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.
Dominguez-Valentin M; Sampson JR; Seppälä TT; Ten Broeke SW; Plazzer JP; Nakken S; Engel C; Aretz S; Jenkins MA; Sunde L; Bernstein I; Capella G; Balaguer F; Thomas H; Evans DG; Burn J; Greenblatt M; Hovig E; de Vos Tot Nederveen Cappel WH; Sijmons RH; Bertario L; Tibiletti MG; Cavestro GM; Lindblom A; Della Valle A; Lopez-Köstner F; Gluck N; Katz LH; Heinimann K; Vaccaro CA; Büttner R; Görgens H; Holinski-Feder E; Morak M; Holzapfel S; Hüneburg R; Knebel Doeberitz MV; Loeffler M; Rahner N; Schackert HK; Steinke-Lange V; Schmiegel W; Vangala D; Pylvänäinen K; Renkonen-Sinisalo L; Hopper JL; Win AK; Haile RW; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Wadt K; Therkildsen C; Okkels H; Ketabi Z; Moreira L; Sánchez A; Serra-Burriel M; Pineda M; Navarro M; Blanco I; Green K; Lalloo F; Crosbie EJ; Hill J; Denton OG; Frayling IM; Rødland EA; Vasen H; Mints M; Neffa F; Esperon P; Alvarez K; Kariv R; Rosner G; Pinero TA; Gonzalez ML; Kalfayan P; Tjandra D; Winship IM; Macrae F; Möslein G; Mecklin JP; Nielsen M; Møller P
Genet Med; 2020 Jan; 22(1):15-25. PubMed ID: 31337882
[TBL] [Abstract] [Full Text] [Related]
10. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Lotan TL; Kaur HB; Alharbi AM; Pritchard CC; Epstein JI
Histopathology; 2019 May; 74(6):836-843. PubMed ID: 30636012
[TBL] [Abstract] [Full Text] [Related]
11. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract] [Full Text] [Related]
12. Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous prostate cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
Liu W; Zhang D; Tan SA; Liu X; Lai J
Anticancer Res; 2018 Aug; 38(8):4847-4852. PubMed ID: 30061258
[TBL] [Abstract] [Full Text] [Related]
13. [Molecular Pathogenesis of Colorectal cancer].
Král J; Slyšková J; Vodička P; Špičák J
Klin Onkol; 2016; 29(6):419-427. PubMed ID: 27951718
[TBL] [Abstract] [Full Text] [Related]
